昭衍新藥(603127.SH):實控人馮宇霞解質850.7296萬股
格隆匯 1 月 22日丨昭衍新藥(603127.SH)公佈,2021年1月22日,公司接到公司股東馮宇霞將其持有公司部分股份解質押的通知,此次解質850.7296萬股。
截至公吿日,公司實際控制人馮宇霞及其配偶周志文合計持有公司股份9864.2454萬股,佔公司總股本的43.37%,其中馮宇霞持有公司股份6407.3468萬股,佔公司總股本的28.17%;周志文持有公司股份3456.8986萬股,佔公司總股本的15.2%。周志文未質押公司股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.